Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women

J Bone Miner Res. 2002 Jul;17(7):1151-61. doi: 10.1359/jbmr.2002.17.7.1151.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Biological Assay
  • Consumer Product Safety
  • Disease Models, Animal
  • Female
  • Humans
  • Male
  • Osteoporosis / drug therapy*
  • Osteoporosis, Postmenopausal / drug therapy*
  • Parathyroid Hormone / therapeutic use*
  • Peptide Fragments / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Risk Assessment

Substances

  • Parathyroid Hormone
  • Peptide Fragments
  • Recombinant Proteins